Why the wellness industry moves faster than the science

By the time most people hear about a new peptide, supplement, or longevity protocol, it's usually already trending testimonials, before-and-afters, a clinic offering it down the street. The actual research, if it exists at all, is often still years away from a real answer. That gap isn't an accident. It's baked into how each side operates.

Two completely different timelines

A new drug, on average, takes over a decade to move from initial discovery to market approval, including multiple phases of human trials designed specifically to catch rare or slow-developing harms. A wellness trend can go from "interesting molecule in a 1990s rat study" to "available at three clinics in your city" in a matter of months. Those two timelines were never going to match, and the industry doesn't wait for them to.

Take BPC-157 as a case study. The animal research goes back roughly three decades and includes well over 100 preclinical studies on tendon, ligament, and gut healing. The human research, when a 2025 review specifically searched for it, turned up exactly one qualifying clinical study. The conversation in wellness spaces, though, talks about BPC-157 as though it's settled science. That confidence didn't come from the data. It came from somewhere else.

Where the confidence actually comes from

No pre-market approval required for the claim to spread. A supplement or "research compound" doesn't need Health Canada or FDA sign-off to be marketed, discussed online, or sold by a clinic it only needs that approval if it's making explicit drug claims and being sold as a licensed drug. That's a low bar, and it means enthusiasm can outrun evidence with no regulatory checkpoint in between.

Anecdote feels like data, especially in large numbers. A thousand testimonials feels more convincing than one twelve-person case series, even though the case series is more rigorous. Our brains weren't built to weigh "n=1,000 unblinded social media posts" against "n=12 controlled patients" correctly, the volume wins, even when the methodology doesn't.

The incentive structures point in different directions. A clinic or supplement company has a direct financial incentive to bring a product to market quickly. A researcher running a properly powered, placebo-controlled trial has an incentive to get the methodology right, which takes years and significant funding, funding that's harder to secure for a compound nobody can patent.

Novelty is rewarded online; replication isn't. "New peptide might reverse aging" gets shared. "Researchers confirmed what we already knew" doesn't. The information ecosystem selects for novelty, not for the slow, repetitive work that actually builds confidence in a finding.

This isn't a new pattern

It's worth saying plainly: this exact pattern — early enthusiasm, aggressive marketing, and widespread adoption well ahead of rigorous evidence — has happened before with other substances and treatments, more than once. It tends to follow a predictable arc: excitement, adoption, a slow trickle of better data, and then a more sober reassessment once the dust settles. Recognizing the pattern doesn't mean every new compound is a dead end. It means the timeline of "available" and the timeline of "understood" are reliably out of sync, and it pays to know which one you're standing on.

How to actually evaluate something new

A few questions I use myself, and walk patients through:

• Is there human data, or only animal data? Animal studies are a reasonable first step, not a conclusion. Mechanisms that work beautifully in rodents frequently fail to translate to humans.

• How many people, and for how long? A twelve-person case series with no control group and a 3,000-person randomized controlled trial followed for two years are not interchangeable categories of evidence, even when both get called "a study."

• Who's making the claim, and what do they gain from you believing it? Not every financial interest invalidates a claim, but it's a relevant piece of context.

• What does a systematic review say, not just a single study? A single study can be an outlier. A systematic review pooling many studies gives you a far more honest picture of where the evidence actually stands.

What this looks like in my practice

I'm not anti-innovation, and I'm not anti-new — naturopathic medicine itself sits at an interesting intersection of long clinical traditions and a growing body of modern research. But I try to be honest with patients about where any given recommendation sits on that evidence spectrum: well-established, promising but early, or genuinely unknown. Sometimes the most useful thing I can offer isn't a new protocol — it's a clear-eyed read on whether the new thing they heard about is actually ready for them yet.

Frequently asked questions

Does "more research is needed" mean a treatment doesn't work? Not necessarily — it means we don't have enough rigorous human evidence yet to be confident either way. That's different from evidence showing it doesn't work, and it's worth treating those two situations differently.

Why do some unproven treatments still get recommended by health professionals? Practice patterns vary widely, and not every recommendation a patient receives reflects the same standard of evidence. It's reasonable to ask any provider what data supports a specific recommendation for your specific situation.

Is it ever reasonable to try something with limited human data? That's a personal risk decision, and a reasonable one to make with full information. The key is making it with accurate information about how limited that data actually is, not with the confidence level the marketing implies.

How long does it usually take for early research to mature into solid evidence? There's no fixed timeline, but going from early animal studies to a body of well-designed human trials commonly takes a decade or more, particularly for anything without a clear path to drug approval.

This article is for educational purposes and is not medical advice. If you're considering a new treatment or supplement, please discuss it with a qualified healthcare provider familiar with your health history.

Want a second, evidence-grounded opinion before you commit to something new? Book a free 15-minute discovery call and let's talk it through. Book here